Basal Cell Carcinoma

P2, N=60, Not yet recruiting, Jules Bordet Institute | Initiation date: Mar 2026 --> Jun 2026

P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center

P3, N=1630, Not yet recruiting, VA Office of Research and Development | Trial completion date: May 2032 --> Aug 2032 | Trial primary completion date: May 2032 --> Aug 2032

Coupled with the decrease in tumour size, a decrease in the expression of CD105, an endothelial marker (p < 0.0001), was observed. In conclusion, neoadjuvant itraconazole for 2 months was able to reduce the diameter of low-risk BCC, and the effect was associated with a decrease in tumour angiogenesis and a favourable safety profile.

P=N/A, N=20, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

P=N/A, N=30, Not yet recruiting, Henry Ford Health System | Initiation date: Mar 2026 --> Sep 2026

These findings suggest that ketamine exhibits potential anti-proliferative and pro-apoptotic effects on HT-29 colorectal cancer cells in vitro. Further studies are warranted to elucidate the underlying molecular mechanisms and potential clinical implications.

Nonetheless, challenges such as high recurrence rates, treatment-associated toxicities, and substantial healthcare costs persist. A comprehensive understanding of skin cancer's molecular mechanisms, improved diagnostic accuracy, and development of innovative therapeutics remain critical for improving patient outcomes and reducing the global burden of skin cancer.

P2, N=92, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting

Using this framework. Together, these results establish sigNATURE as a framework for improving the reproducibility, cross-cohort comparability, and mechanistic interpretability of single-cell ICI biomarkers.

This is the first study to assess epiplakin expression among epithelial cutaneous cancers. Epiplakin appears to be associated with epithelial-mesenchymal transition and early tumor progression, and its differential expression pattern may provide diagnostic utility.

Apart from rheumatoid arthritis, the risk factors for skin cancer in biologic-treated patients with CIRD are similar to those observed in the general population. Our findings might lead to more targeted dermatological monitoring.